These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26645408)

  • 1. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
    Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
    Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical drug interaction profile of idelalisib in healthy subjects.
    Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
    Ramanathan S; Jin F; Sharma S; Kearney BP
    Clin Pharmacokinet; 2016 Jan; 55(1):33-45. PubMed ID: 26242379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):944-52. PubMed ID: 25821156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib has activity in mantle cell lymphoma.
    Cancer Discov; 2014 May; 4(5):OF8. PubMed ID: 24795031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
    Lopez JP; Jimeno A
    Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of adverse events associated with idelalisib treatment: expert panel opinion.
    Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
    Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
    Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
    Davies A
    Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
    Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 16. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
    Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib approved for trio of blood cancers.
    Cancer Discov; 2014 Oct; 4(10):OF6. PubMed ID: 25274697
    [No Abstract]   [Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.